M. de Los Dolores Fenor de la Maza

454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

A. Stathis, A. Alimonti, J. D. de Bono, 2022, Annals of Oncology.

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer

B. Gurel, S. Miranda, J. Mateo, 2023, European urology open science.

A Transgender Patient with Prostate Cancer: Lessons Learnt.

J. D. de Bono, B. Gurel, S. Miranda, 2023, European urology.